Neal Sheldon Birnbaum, MD
Rheumatology · San Francisco
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 12
- 2 carriers
- Office
- 1
- Since medical school
- 56 years
- Ohio State University College of Medicine, 1970
Offices
1 location · Regents Univ of California UCSF · 276 clinicians in this group
Hospitals listed: Marinhealth Medical Center · Novato Community Hospital · Sonoma Valley Hospital · UCSF Medical Center. That is not proof they admit you there this week.
Plans that list them
12 plans · 2 carriers
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Birnbaum’s office at (415) 476-1000 to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
12 of 12 plans
| Alignment Health BreathEasy (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Clarity (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Harmony (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes CalPlus (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes Care (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Heart & Diabetes Choice (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Honor+ Plan (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health My Choice CalCare (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Imperial Courage Plan (HMO) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
| Imperial Dynamic Plan (HMO) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
| Imperial Senior Value (HMO C-SNP) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
California Medical Board record
Licence C36561 · Current
Licensed to practise in California · since 1975 · expires 2027-12-31 · Ohio State University College of Medicine.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Hospitals they work in
4 hospitals
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Marinhealth Medical CenterGreenbrae, CAAcute Care Hospital · Government - Hospital District or Authority · Has an emergency department · Birthing-friendlyPart of MarinHealthPatients rate it 3 of 5 · 76% would definitely recommend itOverall rating: 5 of 5 starsWorse than the national rate — Perioperative pulmonary embolism or deep vein thrombosis rate: 5.66 (3.59 to 7.73) · 1,505 cases, Jul 2022 – Jun 2024Better than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.177, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.446, Oct 2024 – Sep 2025
- Novato Community HospitalNovato, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency departmentPart of Sutter Health, which runs 27 hospitals in 2 statesPatients rate it 4 of 5 · 84% would definitely recommend itOverall rating: 5 of 5 starsBetter than the national rate — Clostridium Difficile (C.Diff): 0, Oct 2024 – Sep 2025
- Sonoma Valley HospitalSonoma, CAAcute Care Hospital · Government - Hospital District or Authority · Has an emergency departmentPatients rate it 4 of 5 · 79% would definitely recommend itOverall rating: 2 of 5 starsNo measure marked better or worse than the national rate
- UCSF Medical CenterSan Francisco, CAAcute Care Hospital · Voluntary non-profit - Other · Has an emergency department · Birthing-friendlyPart of University of California Health, which runs 12 hospitalsHome of UCSF Helen Diller Family Comprehensive Cancer Center, a National Cancer Institute designated comprehensive cancer centrePatients rate it 4 of 5 · 81% would definitely recommend itOverall rating: 4 of 5 starsWorse than the national rate — Perioperative pulmonary embolism or deep vein thrombosis rate: 4.9 (3.79 to 6.02) · 7,590 cases, Jul 2022 – Jun 2024Worse than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 12.8 (11.3 to 14.4) · 2,019 cases, Jan 2024 – Dec 2024Better than the national rate — Death rate among surgical inpatients with serious treatable complications: 139.4 (110.22 to 168.58) · 452 cases, Jul 2022 – Jun 2024Better than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.622, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.626, Oct 2024 – Sep 2025Better than the national rate — MRSA Bacteremia: 0.491, Oct 2024 – Sep 2025Better than the national rate — Ratio of unplanned hospital visits after hospital outpatient surgery: 0.8 (0.7 to 1) · 2,336 cases, Jan 2024 – Dec 2024
See every measure and the patient survey for Marinhealth Medical Center
Behind the star rating — Deaths: 2 better, 6 the same, 0 worse of 8 measures. Safety: 1 better, 6 the same, 0 worse of 7 measures. Readmissions: 3 better, 8 the same, 0 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 5.66 (3.59 to 7.73) · 1,505 cases | Worse | Jul 2022 – Jun 2024 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.177 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.446 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 0.85 (0 to 1.83) · 1,056 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 1.04 (0.72 to 1.36) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 167.34 (112.58 to 222.09) · 57 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 1.9 · 47 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 8.5 · 119 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 9.6 · 257 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 9.5 · 428 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 11.4 · 477 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 9.3 · 197 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3.1 · 2,827 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.18 (0 to 0.38) · 6,990 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.21 (0.02 to 0.41) · 6,838 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.41 (0 to 3) · 664 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.86 (1.4 to 4.33) · 1,436 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 10.38 (3.68 to 17.08) · 705 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 4.38 (0.72 to 8.04) · 672 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.66 (0.18 to 3.15) · 300 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.56 (0 to 1.25) · 5,550 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.4 · 76 cases | None | Apr 2023 – Mar 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.396 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 13.1 · 275 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 22 · 427 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | -20.3 · 289 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | 3.3 · 494 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | -4.9 · 499 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 17.9 · 435 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.5 (3.6 to 8.4) · 93 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 11.2 (7.8 to 16) · 93 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 6.6 · 84 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 10.5 · 53 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.3 · 111 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 13 (10.3 to 16.5) · 2,119 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1.1 (0.8 to 1.4) · 670 cases | No different | Jan 2024 – Dec 2024 |
What patients said (1,233 patients answered, 19% of those asked)
| Cleanliness | 3 |
| Nurse communication | 3 |
| Doctor communication | 3 |
| Communication about medicines | 2 |
| Discharge information | 3 |
| Overall hospital rating | 4 |
| Quietness | 3 |
| Recommend hospital | 4 |
| Room was "always" clean | 68% |
| Nurses "always" communicated well | 73% |
| Doctors "always" communicated well | 74% |
| Staff "always" explained | 56% |
| Yes, staff "did" give patients this information | 85% |
| Yes, staff "did" give patients information about help after discharge | 85% |
| Doctors "always" explained things so they could understand | 71% |
| Doctors "always" listened carefully | 72% |
| Doctors "always" treated them with courtesy and respect | 80% |
| Patients who gave a rating of "9" or "10" (high) | 72% |
| Staff "always" explained new medications | 70% |
| Nurses "always" explained things so they could understand | 68% |
| Nurses "always" listened carefully | 68% |
| Nurses "always" treated them with courtesy and respect | 82% |
| "Always" quiet at night | 48% |
| "YES", patients would definitely recommend the hospital | 76% |
| Staff "always" explained possible side effects | 43% |
| Yes, staff "did" give patients information about possible symptoms | 85% |
See every measure and the patient survey for Novato Community Hospital
Behind the star rating — Deaths: 0 better, 5 the same, 0 worse of 5 measures. Safety: 0 better, 3 the same, 0 worse of 3 measures. Readmissions: 0 better, 7 the same, 0 worse of 7 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Clostridium Difficile (C.Diff)Infections | 0 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1 (0 to 2.06) · 213 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.85 (0.4 to 1.3) | No different | Jul 2022 – Jun 2024 |
| Death rate for COPD patientsComplications and deaths | 8.2 · 25 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 10 · 111 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 16.1 · 140 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 11.3 · 42 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3.8 · 627 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.2 (0 to 0.43) · 1,872 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.25 (0.04 to 0.46) · 1,796 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 2.92 (0.5 to 5.33) · 505 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.64 (0 to 3.36) · 317 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.2 (0.51 to 3.88) · 495 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 7.93 (0 to 17.29) · 323 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 4.88 (0.69 to 9.07) · 311 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.75 (0.22 to 3.27) · 96 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.41 (0 to 1.49) · 1,320 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.2 · 143 cases | None | Apr 2023 – Mar 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 19.6 · 108 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -31.9 · 121 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 1.1 · 150 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.6 · 143 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.4 · 118 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.6 · 27 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.5 (9.5 to 16.5) · 930 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1 (0.7 to 1.3) · 184 cases | No different | Jan 2024 – Dec 2024 |
What patients said (334 patients answered, 30% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 3 |
| Recommend hospital | 5 |
| Room was "always" clean | 78% |
| Nurses "always" communicated well | 81% |
| Doctors "always" communicated well | 83% |
| Staff "always" explained | 63% |
| Yes, staff "did" give patients this information | 89% |
| Yes, staff "did" give patients information about help after discharge | 89% |
| Doctors "always" explained things so they could understand | 78% |
| Doctors "always" listened carefully | 84% |
| Doctors "always" treated them with courtesy and respect | 87% |
| Patients who gave a rating of "9" or "10" (high) | 82% |
| Staff "always" explained new medications | 77% |
| Nurses "always" explained things so they could understand | 76% |
| Nurses "always" listened carefully | 82% |
| Nurses "always" treated them with courtesy and respect | 86% |
| "Always" quiet at night | 54% |
| "YES", patients would definitely recommend the hospital | 84% |
| Staff "always" explained possible side effects | 49% |
| Yes, staff "did" give patients information about possible symptoms | 90% |
See every measure and the patient survey for Sonoma Valley Hospital
Behind the star rating — Deaths: 0 better, 5 the same, 0 worse of 5 measures. Safety: 0 better, 2 the same, 0 worse of 2 measures. Readmissions: 0 better, 6 the same, 0 worse of 6 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 1.11 (0.63 to 1.6) | No different | Jul 2022 – Jun 2024 |
| Death rate for COPD patientsComplications and deaths | 8.2 · 37 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 11 · 41 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 16.6 · 106 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 9.6 · 35 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 5.6 · 345 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.21 (0 to 0.44) · 713 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.27 (0.05 to 0.48) · 660 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.36 (0.77 to 5.94) · 101 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.65 (0 to 3.38) · 27 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.31 (0.58 to 4.03) · 100 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 8.86 (0 to 18.76) · 28 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.15 (0.84 to 9.45) · 27 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 1.12 (0 to 2.33) · 540 cases | No different | Jul 2022 – Jun 2024 |
| Clostridium Difficile (C.Diff)Infections | 0.651 | No different | Oct 2024 – Sep 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 21.1 · 60 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | 15.5 · 47 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 7.1 · 100 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 18 · 105 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.7 · 47 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 13.6 (10.2 to 17.9) · 486 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.9 (0.6 to 1.3) · 83 cases | No different | Jan 2024 – Dec 2024 |
What patients said (164 patients answered, 31% of those asked)
| Cleanliness | 4 |
| Nurse communication | 5 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 3 |
| Recommend hospital | 4 |
| Room was "always" clean | 74% |
| Nurses "always" communicated well | 85% |
| Doctors "always" communicated well | 88% |
| Staff "always" explained | 65% |
| Yes, staff "did" give patients this information | 89% |
| Yes, staff "did" give patients information about help after discharge | 88% |
| Doctors "always" explained things so they could understand | 84% |
| Doctors "always" listened carefully | 88% |
| Doctors "always" treated them with courtesy and respect | 92% |
| Patients who gave a rating of "9" or "10" (high) | 74% |
| Staff "always" explained new medications | 77% |
| Nurses "always" explained things so they could understand | 81% |
| Nurses "always" listened carefully | 82% |
| Nurses "always" treated them with courtesy and respect | 91% |
| "Always" quiet at night | 52% |
| "YES", patients would definitely recommend the hospital | 79% |
| Staff "always" explained possible side effects | 53% |
| Yes, staff "did" give patients information about possible symptoms | 90% |
See every measure and the patient survey for UCSF Medical Center
Behind the star rating — Deaths: 5 better, 3 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 3 better, 5 the same, 3 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 4.9 (3.79 to 6.02) · 7,590 cases | Worse | Jul 2022 – Jun 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 12.8 (11.3 to 14.4) · 2,019 cases | Worse | Jan 2024 – Dec 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 139.4 (110.22 to 168.58) · 452 cases | Better | Jul 2022 – Jun 2024 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.622 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.626 | Better | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.491 | Better | Oct 2024 – Sep 2025 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.8 (0.7 to 1) · 2,336 cases | Better | Jan 2024 – Dec 2024 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.24 (0.58 to 1.9) · 4,689 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 1.05 (0.89 to 1.2) | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 1.9 · 89 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 7.5 · 85 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 10.1 · 132 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 6.6 · 454 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 10.3 · 618 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 9.6 · 380 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.7 · 5,000 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.22 (0.06 to 0.38) · 15,965 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.2 (0.05 to 0.35) · 17,859 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 0.85 (0 to 1.83) · 4,184 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2 (1.1 to 2.9) · 6,516 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 7.35 (4.49 to 10.21) · 3,989 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5 (3.22 to 6.77) · 4,087 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.95 (0.74 to 3.15) · 2,034 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.95 (0.63 to 1.28) · 15,431 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 4 · 399 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.899 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 0.689 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 1.224 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 16 · 156 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20 · 564 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 60.3 · 160 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -9.7 · 550 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 44.1 · 660 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.8 · 667 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.7 (4.8 to 6.7) · 2,019 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 6 · 421 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 10.5 · 53 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 20 · 107 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 13.9 (11.3 to 17.1) · 3,247 cases | No different | Jan 2022 – Dec 2024 |
What patients said (3,181 patients answered, 25% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 2 |
| Recommend hospital | 5 |
| Room was "always" clean | 71% |
| Nurses "always" communicated well | 80% |
| Doctors "always" communicated well | 80% |
| Staff "always" explained | 61% |
| Yes, staff "did" give patients this information | 88% |
| Yes, staff "did" give patients information about help after discharge | 87% |
| Doctors "always" explained things so they could understand | 74% |
| Doctors "always" listened carefully | 78% |
| Doctors "always" treated them with courtesy and respect | 86% |
| Patients who gave a rating of "9" or "10" (high) | 76% |
| Staff "always" explained new medications | 75% |
| Nurses "always" explained things so they could understand | 77% |
| Nurses "always" listened carefully | 78% |
| Nurses "always" treated them with courtesy and respect | 86% |
| "Always" quiet at night | 50% |
| "YES", patients would definitely recommend the hospital | 81% |
| Staff "always" explained possible side effects | 46% |
| Yes, staff "did" give patients information about possible symptoms | 90% |
Original Medicare doctor bills
$484,836
Medicare paid this office $484,836 for 272 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Injection, golimumab, 1 mg, for intravenous use | 25 | $225,151 | None |
| Injection, denosumab, 1 mg | 28 | $57,640 | None |
| Return visit (30+ min) | 198 | $40,895 | $112 |
| Administration of chemotherapy into vein, 1 hour or less | 40 | $21,615 | $139 |
| Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle | 34 | $6,408 | $75 |
See all 13 services
| Injection, golimumab, 1 mg, for intravenous use | 25 | $225,151 | None |
| Injection, denosumab, 1 mg | 28 | $57,640 | None |
| Return visit (30+ min) | 198 | $40,895 | $112 |
| Administration of chemotherapy into vein, 1 hour or less | 40 | $21,615 | $139 |
| Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle | 34 | $6,408 | $75 |
| New patient visit (45+ min) | 45 | $6,161 | $137 |
| Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | 218 | $5,613 | $14 |
| Short return visit (20+ min) | 60 | $5,250 | $75 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 36 | $4,137 | $52 |
| New patient visit (60+ min) | 18 | $3,535 | $196 |
| Aspiration and/or injection of fluid from large joint | 18 | $1,676 | $70 |
| Injection, zoledronic acid, 1 mg | 11 | $230 | None |
| Injection, triamcinolone acetonide, not otherwise specified, 10 mg | 25 | $112 | None |
Procedures year by year
| Procedure | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|
| Aspiration and/or injection of fluid from large joint | 33 | 26 | 23 | 39 | 27 | 24 |
| Injection into tendon or ligament | 21 | – | – | – | – | – |
| Aspiration and/or injection of fluid from small joint | 14 | – | – | – | – | – |
Times billed to Original Medicare each year. A blank year means fewer than 11 people had it, or none: Medicare does not publish smaller counts. Medicare Advantage patients are not included.
Who their Medicare patients are
272 Original Medicare patients in 2024. Average age 76 · Women 68% · Also on Medicaid 7% · Health risk score 1.27. At or below the middle of the specialty; the typical rheumatology clinician is at 1.38.
Conditions among them: High blood pressure 64% · Coronary heart disease 24% · Diabetes 18% · Cancer 17% · Chronic kidney disease 16% · Atrial fibrillation 14% · Depression 14% · Heart failure 11% · COPD 8% · Stroke 6% · Dementia 4%.
The office billed $1,088,611, Medicare allowed $618,851 and paid $484,836; for 46,750 services of 28 kinds; $385,275 of it was for drugs given in the office and $99,561 for care.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 272 | 46,750 | 76 | 1.27 | $1,088,611 | $484,836 |
| 2023 | 270 | 35,592 | 76 | 1.24 | $947,284 | $398,094 |
| 2022 | 276 | 28,683 | 76 | 1.21 | $833,321 | $359,181 |
| 2021 | 245 | 29,956 | 76 | 1.25 | $817,148 | $414,153 |
| 2020 | 257 | 29,112 | 75 | 1.34 | $894,998 | $475,185 |
| 2019 | 283 | 29,807 | 74 | 1.30 | $815,537 | $458,084 |
| 2018 | 372 | 36,962 | 74 | 1.40 | $1,014,825 | $617,915 |
| 2017 | 368 | 26,891 | 74 | 1.39 | $804,436 | $495,064 |
| 2016 | 334 | 12,784 | 73 | 1.25 | $598,296 | $360,146 |
| 2015 | 378 | 4,713 | 73 | 1.16 | $383,851 | $203,180 |
| 2014 | 347 | 10,315 | 72 | 1.14 | $437,256 | $228,246 |
| 2013 | 358 | 3,488 | 73 | 1.07 | $360,939 | $192,082 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 12 services
| Injection, golimumab, 1 mg, for intravenous use | 27 | $228,836 | None |
| Injection, denosumab, 1 mg | 21 | $38,845 | None |
| Return visit (30+ min) | 148 | $23,801 | $106 |
| Short return visit (20+ min) | 121 | $12,677 | $76 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 42 | $10,211 | $60 |
| New patient visit (45+ min) | 41 | $5,662 | $138 |
| New patient visit (60+ min) | 21 | $3,908 | $186 |
| Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle | 27 | $3,222 | $69 |
| Aspiration and/or injection of fluid from large joint | 18 | $1,722 | $64 |
| Long return visit (40+ min) | 11 | $1,561 | $142 |
| Injection, zoledronic acid, 1 mg | 12 | $245 | None |
| Injection, triamcinolone acetonide, not otherwise specified, 10 mg | 32 | $136 | None |
2022: 13 services
| Injection, golimumab, 1 mg, for intravenous use | 23 | $222,851 | None |
| Injection, denosumab, 1 mg | 14 | $23,680 | None |
| Return visit (30+ min) | 137 | $22,647 | $101 |
| Short return visit (20+ min) | 126 | $13,495 | $67 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 40 | $9,111 | $62 |
| New patient visit (45+ min) | 43 | $5,889 | $137 |
| New patient visit (60+ min) | 28 | $5,149 | $184 |
| Aspiration and/or injection of fluid from large joint | 25 | $2,212 | $57 |
| Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle | 11 | $864 | $79 |
| Telephone medical discussion with physician, 11-20 minutes | 12 | $522 | $40 |
| Injection, zoledronic acid, 1 mg | 13 | $315 | None |
| Injection of drug or substance under skin or into muscle | 13 | $208 | $12 |
| Injection, triamcinolone acetonide, not otherwise specified, 10 mg | 41 | $202 | None |
2021: 10 services
| Injection, golimumab, 1 mg, for intravenous use | 17 | $174,498 | None |
| Return visit (30+ min) | 106 | $18,387 | $108 |
| Short return visit (20+ min) | 99 | $10,908 | $74 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 29 | $9,857 | $74 |
| New patient visit (60+ min) | 43 | $8,676 | $202 |
| New patient visit (45+ min) | 20 | $2,979 | $149 |
| Telephone medical discussion with physician, 11-20 minutes | 33 | $2,761 | $60 |
| Aspiration and/or injection of fluid from large joint | 16 | $1,303 | $57 |
| Injection of drug or substance under skin or into muscle | 14 | $372 | $14 |
| Injection, triamcinolone acetonide, not otherwise specified, 10 mg | 31 | $147 | None |
2020: 11 services
| Injection, golimumab, 1 mg, for intravenous use | 19 | $186,491 | None |
| Injection, infliximab, excludes biosimilar, 10 mg | 11 | $73,574 | None |
| Return visit (30+ min) | 124 | $14,719 | $82 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 27 | $10,499 | $71 |
| Short return visit (20+ min) | 131 | $9,727 | $53 |
| New patient visit (60+ min) | 40 | $6,758 | $169 |
| Telephone medical discussion with physician, 21-30 minutes | 22 | $2,609 | $104 |
| Telephone medical discussion with physician, 11-20 minutes | 31 | $2,476 | $71 |
| Aspiration and/or injection of fluid from large joint | 18 | $1,511 | $58 |
| Injection of drug or substance under skin or into muscle | 12 | $360 | $14 |
| Injection, triamcinolone acetonide, not otherwise specified, 10 mg | 30 | $199 | None |
2019: 13 services
| Injection, golimumab, 1 mg, for intravenous use | 16 | $184,804 | None |
| Return visit (30+ min) | 122 | $16,224 | $91 |
| Short return visit (20+ min) | 163 | $15,780 | $61 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 27 | $10,333 | $71 |
| New patient visit (60+ min) | 56 | $9,898 | $177 |
| New patient visit (45+ min) | 17 | $2,462 | $145 |
| Aspiration and/or injection of fluid from large joint | 22 | $1,798 | $54 |
| Injection into tendon or ligament | 18 | $926 | $44 |
| Aspiration and/or injection of fluid from small joint | 13 | $595 | $42 |
| Influenza vaccine, quadrivalent derived from cell cultures | 15 | $392 | $26 |
| Injection of drug or substance under skin or into muscle | 12 | $361 | $15 |
| Injection, triamcinolone acetonide, not otherwise specified, 10 mg | 55 | $277 | None |
| Administration of influenza virus vaccine | 15 | $241 | $15 |
2018: 15 services
| Injection, golimumab, 1 mg, for intravenous use | 21 | $264,093 | None |
| Injection, infliximab, excludes biosimilar, 10 mg | 12 | $137,958 | None |
| Short return visit (20+ min) | 160 | $17,577 | $65 |
| New patient visit (60+ min) | 91 | $16,829 | $185 |
| Return visit (30+ min) | 132 | $16,628 | $96 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 36 | $13,191 | $78 |
| Administration of chemotherapy into vein, 1 hour or less | 12 | $11,795 | $153 |
| New patient visit (45+ min) | 31 | $4,537 | $146 |
| Long return visit (40+ min) | 21 | $3,635 | $135 |
| Administration of chemotherapy into vein, each additional hour | 12 | $2,549 | $33 |
| Aspiration and/or injection of fluid from large joint | 28 | $1,988 | $55 |
| Injection into tendon or ligament | 14 | $1,069 | $51 |
| Aspiration and/or injection of fluid from medium joint | 13 | $602 | $43 |
| Injection, triamcinolone acetonide, not otherwise specified, 10 mg | 54 | $314 | None |
| Administration of influenza virus vaccine | 12 | $176 | $15 |
2017: 15 services
| Injection, golimumab, 1 mg, for intravenous use | 15 | $174,216 | None |
| Injection, infliximab, excludes biosimilar, 10 mg | 18 | $123,148 | None |
| Return visit (30+ min) | 169 | $19,144 | $92 |
| Short return visit (20+ min) | 166 | $16,945 | $58 |
| New patient visit (60+ min) | 72 | $12,463 | $173 |
| Administration of chemotherapy into vein, 1 hour or less | 18 | $9,090 | $140 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 28 | $9,030 | $71 |
| New patient visit (45+ min) | 27 | $3,386 | $125 |
| Aspiration and/or injection of fluid from large joint | 31 | $2,150 | $55 |
| Administration of chemotherapy into vein, each additional hour | 18 | $1,854 | $29 |
| Injection into tendon or ligament | 13 | $613 | $44 |
| Aspiration and/or injection of fluid from medium joint | 12 | $482 | $40 |
| Injection, triamcinolone acetonide, not otherwise specified, 10 mg | 63 | $359 | None |
| Influenza virus vaccine, not otherwise specified | 13 | $280 | $22 |
| Administration of influenza virus vaccine | 17 | $250 | $15 |
2016: 13 services
| Injection, golimumab, 1 mg, for intravenous use | 12 | $138,925 | None |
| Injection, infliximab, excludes biosimilar, 10 mg | 11 | $83,206 | None |
| Return visit (30+ min) | 154 | $20,985 | $89 |
| New patient visit (60+ min) | 87 | $15,757 | $181 |
| Short return visit (20+ min) | 154 | $14,575 | $58 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 18 | $6,373 | $71 |
| New patient visit (45+ min) | 18 | $2,519 | $140 |
| Aspiration and/or injection of fluid from large joint | 28 | $2,139 | $59 |
| Injection into tendon or ligament | 16 | $1,321 | $55 |
| Aspiration and/or injection of fluid from small joint | 12 | $563 | $40 |
| Injection, triamcinolone acetonide, not otherwise specified, 10 mg | 58 | $390 | None |
| Administration of influenza virus vaccine | 18 | $265 | $15 |
| Influenza virus vaccine, split virus, when administered to individuals 3 years of age and older, for intramuscular use (fluvirin) | 12 | $191 | $16 |
2015: 14 services
| Injection, infliximab, excludes biosimilar, 10 mg | 13 | $88,388 | None |
| Return visit (30+ min) | 155 | $20,396 | $91 |
| New patient visit (60+ min) | 92 | $16,358 | $178 |
| Short return visit (20+ min) | 148 | $14,925 | $59 |
| Administration of chemotherapy into vein, 1 hour or less | 12 | $9,886 | $139 |
| New patient visit (45+ min) | 44 | $6,023 | $137 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 14 | $2,332 | $67 |
| Aspiration and/or injection of fluid from large joint | 26 | $2,229 | $57 |
| Administration of chemotherapy into vein, each additional hour | 12 | $2,023 | $28 |
| Injection into tendon or ligament | 16 | $1,391 | $45 |
| Aspiration and/or injection of fluid from medium joint | 14 | $563 | $40 |
| Injection, triamcinolone acetonide, not otherwise specified, 10 mg | 61 | $452 | None |
| Administration of influenza virus vaccine | 21 | $309 | $14 |
| Influenza virus vaccine, split virus, when administered to individuals 3 years of age and older, for intramuscular use (flulaval) | 21 | $177 | $8 |
2014: 14 services
| Injection, infliximab, excludes biosimilar, 10 mg | 16 | $110,094 | None |
| Return visit (30+ min) | 150 | $19,247 | $88 |
| Short return visit (20+ min) | 154 | $15,689 | $56 |
| Administration of chemotherapy into vein, 1 hour or less | 17 | $12,075 | $134 |
| New patient visit (60+ min) | 51 | $9,175 | $180 |
| New patient visit (45+ min) | 59 | $7,174 | $122 |
| Aspiration and/or injection of fluid from large joint | 40 | $2,898 | $56 |
| Administration of chemotherapy into vein, each additional hour | 16 | $2,515 | $28 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 11 | $2,434 | $72 |
| Injection into tendon or ligament | 15 | $1,052 | $48 |
| Aspiration and/or injection of fluid from small joint | 13 | $717 | $38 |
| Injection, triamcinolone acetonide, not otherwise specified, 10 mg | 68 | $506 | None |
| Administration of influenza virus vaccine | 25 | $382 | $15 |
| Influenza virus vaccine, split virus, when administered to individuals 3 years of age and older, for intramuscular use (flulaval) | 25 | $219 | $8 |
2013: 14 services
| Injection, infliximab, excludes biosimilar, 10 mg | 11 | $108,485 | None |
| Return visit (30+ min) | 150 | $19,266 | $88 |
| Short return visit (20+ min) | 157 | $16,794 | $59 |
| Administration of chemotherapy into vein, 1 hour or less | 18 | $14,760 | $145 |
| New patient visit (45+ min) | 76 | $10,957 | $144 |
| New patient visit (60+ min) | 36 | $5,833 | $162 |
| Aspiration and/or injection of fluid from large joint | 40 | $3,162 | $55 |
| Administration of chemotherapy into vein, each additional hour | 17 | $2,833 | $31 |
| Injection into tendon or ligament | 19 | $1,412 | $50 |
| Aspiration and/or injection of fluid from medium joint | 15 | $1,110 | $62 |
| Aspiration and/or injection of fluid from small joint | 17 | $791 | $40 |
| Injection, triamcinolone acetonide, not otherwise specified, 10 mg | 82 | $556 | None |
| Administration of influenza virus vaccine | 13 | $191 | $15 |
| Influenza virus vaccine, split virus, when administered to individuals 3 years of age and older, for intramuscular use (flulaval) | 14 | $124 | $9 |
Medicaid work
$965 in 2019
Medicaid paid $965 for 12 billed services this clinician did in 2019, up to 12 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Clinic visit/encounter, all-inclusive | 12 | $965 |
| 2019 | 12 | 1 | 12 | $965 |
Drugs they prescribed that Part D paid
$3,221,670
Pharmacies billed $3,221,670 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 3% of their Part D prescriptions (48 of 1,502) in 2024. Above the middle of the specialty; the typical rheumatology clinician is at 3%.
1,050 generic and fewer than 11 brand-name prescriptions · $3,221,670 in drug cost.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Humira(Cf) | 87 | $642,522 | $7,385 |
| Enbrel | 74 | $562,755 | $7,605 |
| Enbrel Sureclick | 60 | $456,260 | $7,604 |
| Rinvoq | 53 | $396,268 | $7,477 |
| Humira(Cf) | 38 | $264,144 | $6,951 |
See all 25 drugs
| Humira(Cf) | 87 | $642,522 | $7,385 |
| Enbrel | 74 | $562,755 | $7,605 |
| Enbrel Sureclick | 60 | $456,260 | $7,604 |
| Rinvoq | 53 | $396,268 | $7,477 |
| Humira(Cf) | 38 | $264,144 | $6,951 |
| Xeljanz Xr | 35 | $240,292 | $6,865 |
| Simponi Aria | 21 | $130,961 | $6,236 |
| Simponi | 21 | $121,444 | $5,783 |
| Xeljanz | 15 | $115,455 | $7,697 |
| Enbrel Mini | 12 | $87,536 | $7,295 |
| Hydroxychloroquine Sulfate | 208 | $10,796 | $52 |
| Febuxostat | 20 | $4,041 | $202 |
| Methotrexate | 138 | $3,876 | $28 |
| Prednisone | 300 | $3,539 | $12 |
| Colchicine | 14 | $1,957 | $140 |
| Allopurinol | 90 | $1,346 | $15 |
| Folic Acid | 50 | $810 | $16 |
| Celecoxib | 13 | $456 | $35 |
| Tramadol | 33 | $381 | $12 |
| Hydrocodone-Acetaminophen | 15 | $275 | $18 |
| Methylprednisolone | 26 | $244 | $9 |
| Naproxen | 11 | $205 | $19 |
| Ibuprofen | 11 | $195 | $18 |
| Meloxicam | 12 | $38 | $3 |
| Alendronate | 19 | $24 | $1 |
Year by year
| 2024 | 1,502 | 242 | 3% (48) | None | $3,221,670 |
| 2023 | 1,550 | 254 | 2% (36) | None | $3,262,265 |
| 2022 | 1,567 | 247 | 2% (30) | None | $3,011,051 |
| 2021 | 1,636 | 246 | 3% (51) | 27% | $2,560,979 |
| 2020 | 1,697 | 254 | 3% (49) | None | $2,221,809 |
| 2019 | 1,727 | 258 | 2% (42) | 25% | $1,881,087 |
| 2018 | 1,798 | 311 | 2% (43) | None | $1,780,106 |
| 2017 | 1,874 | 322 | 3% (56) | None | $2,032,912 |
| 2016 | 1,821 | 256 | 4% (63) | 31% | $1,710,967 |
| 2015 | 1,930 | 259 | 3% (58) | 36% | $1,627,540 |
| 2014 | 1,896 | 261 | 3% (53) | 35% | $1,161,975 |
| 2013 | 1,934 | 252 | 4% (78) | None | $854,731 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 23 drugs
| Humira(Cf) | 112 | $857,314 | $7,655 |
| Enbrel | 73 | $566,228 | $7,757 |
| Enbrel Sureclick | 59 | $458,305 | $7,768 |
| Humira(Cf) | 40 | $304,956 | $7,624 |
| Rinvoq | 41 | $288,218 | $7,030 |
| Xeljanz Xr | 32 | $179,061 | $5,596 |
| Simponi | 24 | $151,884 | $6,328 |
| Xeljanz | 16 | $114,926 | $7,183 |
| Simponi Aria | 14 | $90,040 | $6,431 |
| Tymlos | 12 | $35,265 | $2,939 |
| Hydroxychloroquine Sulfate | 212 | $15,505 | $73 |
| Methotrexate | 178 | $9,380 | $53 |
| Prednisone | 319 | $5,115 | $16 |
| Febuxostat | 14 | $4,569 | $326 |
| Colchicine | 18 | $2,337 | $130 |
| Allopurinol | 92 | $1,840 | $20 |
| Celecoxib | 17 | $1,819 | $107 |
| Tramadol | 25 | $650 | $26 |
| Hydrocodone-Acetaminophen | 11 | $391 | $36 |
| Ibuprofen | 11 | $282 | $26 |
| Methylprednisolone | 23 | $265 | $12 |
| Amitriptyline | 11 | $224 | $20 |
| Folic Acid | 32 | $143 | $4 |
2022: 25 drugs
| Humira(Cf) | 121 | $854,553 | $7,062 |
| Enbrel | 80 | $594,777 | $7,435 |
| Enbrel Sureclick | 68 | $472,535 | $6,949 |
| Humira(Cf) | 46 | $316,549 | $6,881 |
| Xeljanz | 19 | $132,814 | $6,990 |
| Simponi | 21 | $124,028 | $5,906 |
| Rinvoq | 18 | $110,994 | $6,166 |
| Xeljanz Xr | 19 | $99,333 | $5,228 |
| Simponi Aria | 15 | $92,298 | $6,153 |
| Tymlos | 12 | $29,396 | $2,450 |
| Hydroxychloroquine Sulfate | 216 | $15,947 | $74 |
| Methotrexate | 184 | $11,391 | $62 |
| Prednisone | 336 | $6,182 | $18 |
| Febuxostat | 11 | $5,434 | $494 |
| Colchicine | 11 | $3,148 | $286 |
| Allopurinol | 93 | $1,857 | $20 |
| Celecoxib | 11 | $911 | $83 |
| Diclofenac | 16 | $438 | $27 |
| Methylprednisolone | 30 | $392 | $13 |
| Hydrocodone-Acetaminophen | 11 | $302 | $27 |
| Amitriptyline | 16 | $232 | $14 |
| Tramadol | 19 | $215 | $11 |
| Alendronate | 11 | $165 | $15 |
| Folic Acid | 21 | $155 | $7 |
| Meloxicam | 17 | $96 | $6 |
2021: 25 drugs
| Humira(Cf) | 133 | $859,972 | $6,466 |
| Enbrel Sureclick | 69 | $433,263 | $6,279 |
| Enbrel | 54 | $377,381 | $6,989 |
| Humira(Cf) | 41 | $271,825 | $6,630 |
| Xeljanz Xr | 25 | $125,286 | $5,011 |
| Simponi Aria | 18 | $102,172 | $5,676 |
| Simponi | 15 | $78,846 | $5,256 |
| Rinvoq | 12 | $67,802 | $5,650 |
| Tymlos | 11 | $24,791 | $2,254 |
| Hydroxychloroquine Sulfate | 207 | $18,629 | $90 |
| Methotrexate | 252 | $13,342 | $53 |
| Colchicine | 15 | $7,196 | $480 |
| Prednisone | 358 | $6,013 | $17 |
| Allopurinol | 87 | $1,603 | $18 |
| Celecoxib | 18 | $1,484 | $82 |
| Hydrocodone-Acetaminophen | 24 | $443 | $18 |
| Methylprednisolone | 26 | $386 | $15 |
| Amitriptyline | 16 | $376 | $23 |
| Ibuprofen | 12 | $315 | $26 |
| Tramadol | 27 | $248 | $9 |
| Meloxicam | 21 | $221 | $11 |
| Diclofenac | 11 | $208 | $19 |
| Omeprazole | 14 | $184 | $13 |
| Atorvastatin | 12 | $134 | $11 |
| Alendronate | 14 | $106 | $8 |
2020: 22 drugs
| Humira(Cf) | 120 | $726,332 | $6,053 |
| Enbrel Sureclick | 60 | $337,696 | $5,628 |
| Enbrel | 42 | $335,585 | $7,990 |
| Xeljanz Xr | 40 | $189,452 | $4,736 |
| Humira(Cf) | 25 | $144,432 | $5,777 |
| Simponi | 23 | $116,349 | $5,059 |
| Simponi Aria | 20 | $95,621 | $4,781 |
| Hydroxychloroquine Sulfate | 236 | $28,318 | $120 |
| Methotrexate | 299 | $17,028 | $57 |
| Prednisone | 358 | $5,344 | $15 |
| Colchicine | 14 | $4,447 | $318 |
| Celecoxib | 22 | $1,895 | $86 |
| Allopurinol | 64 | $1,523 | $24 |
| Hydrocodone-Acetaminophen | 25 | $579 | $23 |
| Meloxicam | 28 | $456 | $16 |
| Methylprednisolone | 25 | $352 | $14 |
| Amitriptyline | 17 | $279 | $16 |
| Ibuprofen | 11 | $240 | $22 |
| Tramadol | 24 | $187 | $8 |
| Alendronate | 13 | $97 | $7 |
| Omeprazole | 15 | $97 | $6 |
| Sodium Chloride | 13 | $22 | $2 |
2019: 26 drugs
| Humira(Cf) | 115 | $613,040 | $5,331 |
| Enbrel Sureclick | 59 | $306,532 | $5,195 |
| Enbrel | 37 | $199,040 | $5,379 |
| Simponi | 30 | $145,509 | $4,850 |
| Remicade | 17 | $142,279 | $8,369 |
| Xeljanz Xr | 22 | $117,449 | $5,339 |
| Simponi Aria | 19 | $84,706 | $4,458 |
| Humira(Cf) | 13 | $68,108 | $5,239 |
| Otezla | 13 | $43,767 | $3,367 |
| Hydroxychloroquine Sulfate | 247 | $34,723 | $141 |
| Methotrexate | 337 | $22,505 | $67 |
| Colchicine | 13 | $6,071 | $467 |
| Prednisone | 347 | $5,430 | $16 |
| Allopurinol | 80 | $1,837 | $23 |
| Celecoxib | 18 | $1,596 | $89 |
| Mycophenolate Mofetil | 11 | $1,309 | $119 |
| Hydrocodone-Acetaminophen | 29 | $799 | $28 |
| Duloxetine | 14 | $692 | $49 |
| Omeprazole | 16 | $371 | $23 |
| Naproxen | 18 | $362 | $20 |
| Methylprednisolone | 17 | $356 | $21 |
| Ibuprofen | 15 | $317 | $21 |
| Meloxicam | 25 | $264 | $11 |
| Amitriptyline | 16 | $263 | $16 |
| Alendronate | 23 | $255 | $11 |
| Tramadol | 13 | $177 | $14 |
2018: 24 drugs
| Humira | 87 | $456,513 | $5,247 |
| Enbrel Sureclick | 75 | $362,727 | $4,836 |
| Simponi | 36 | $164,646 | $4,573 |
| Remicade | 18 | $146,654 | $8,147 |
| Enbrel | 19 | $137,459 | $7,235 |
| Simponi Aria | 19 | $89,693 | $4,721 |
| Humira | 15 | $73,870 | $4,925 |
| Xeljanz Xr | 14 | $66,364 | $4,740 |
| Otezla | 13 | $41,984 | $3,230 |
| Hydroxychloroquine Sulfate | 241 | $39,826 | $165 |
| Methotrexate | 358 | $28,541 | $80 |
| Colcrys | 13 | $8,926 | $687 |
| Prednisone | 360 | $5,322 | $15 |
| Celecoxib | 32 | $5,250 | $164 |
| Allopurinol | 74 | $2,208 | $30 |
| Leucovorin | 12 | $1,228 | $102 |
| Mycophenolate Mofetil | 12 | $1,213 | $101 |
| Hydrocodone-Acetaminophen | 35 | $1,152 | $33 |
| Atorvastatin | 18 | $520 | $29 |
| Methylprednisolone | 29 | $496 | $17 |
| Alendronate | 28 | $368 | $13 |
| Diclofenac | 11 | $331 | $30 |
| Meloxicam | 18 | $213 | $12 |
| Sodium Chloride | 25 | $77 | $3 |
2017: 26 drugs
| Humira | 134 | $632,034 | $4,717 |
| Enbrel Sureclick | 62 | $285,124 | $4,599 |
| Remicade | 26 | $176,862 | $6,802 |
| Enbrel | 33 | $158,743 | $4,810 |
| Simponi | 36 | $150,065 | $4,168 |
| Xeljanz Xr | 32 | $144,771 | $4,524 |
| Humira | 28 | $142,786 | $5,099 |
| Xeljanz | 14 | $88,231 | $6,302 |
| Hydroxychloroquine Sulfate | 243 | $49,907 | $205 |
| Simponi Aria | 11 | $42,671 | $3,879 |
| Methotrexate | 284 | $28,722 | $101 |
| Prednisone | 325 | $5,155 | $16 |
| Celecoxib | 25 | $2,923 | $117 |
| Allopurinol | 86 | $2,618 | $30 |
| Hydrocodone-Acetaminophen | 48 | $1,034 | $22 |
| Mycophenolate Mofetil | 12 | $779 | $65 |
| Atorvastatin | 29 | $737 | $25 |
| Proair Hfa | 12 | $691 | $58 |
| Levothyroxine | 18 | $683 | $38 |
| Azelastine | 13 | $557 | $43 |
| Alendronate | 42 | $505 | $12 |
| Methylprednisolone | 21 | $477 | $23 |
| Omeprazole | 17 | $342 | $20 |
| Gabapentin | 18 | $327 | $18 |
| Sulfasalazine | 13 | $278 | $21 |
| Triamterene-Hydrochlorothiazid | 12 | $194 | $16 |
2016: 26 drugs
| Humira | 115 | $562,832 | $4,894 |
| Enbrel | 69 | $267,862 | $3,882 |
| Remicade | 36 | $231,172 | $6,421 |
| Humira | 42 | $168,252 | $4,006 |
| Simponi | 35 | $131,402 | $3,754 |
| Xeljanz | 19 | $89,096 | $4,689 |
| Hydroxychloroquine Sulfate | 226 | $55,603 | $246 |
| Xeljanz Xr | 12 | $42,241 | $3,520 |
| Methotrexate | 322 | $24,985 | $78 |
| Prednisone | 298 | $4,825 | $16 |
| Colchicine | 15 | $3,049 | $203 |
| Hydrocodone-Acetaminophen | 51 | $2,247 | $44 |
| Celecoxib | 11 | $2,055 | $187 |
| Allopurinol | 75 | $1,978 | $26 |
| Duloxetine | 12 | $1,884 | $157 |
| Methylprednisolone | 50 | $1,034 | $21 |
| Alendronate | 56 | $677 | $12 |
| Valacyclovir | 15 | $573 | $38 |
| Ibuprofen | 16 | $526 | $33 |
| Gabapentin | 20 | $473 | $24 |
| Levothyroxine | 12 | $398 | $33 |
| Atorvastatin | 15 | $357 | $24 |
| Omeprazole | 12 | $306 | $26 |
| Triamterene-Hydrochlorothiazid | 18 | $252 | $14 |
| Naproxen | 15 | $231 | $15 |
| Atenolol | 11 | $102 | $9 |
2015: 25 drugs
| Humira | 116 | $480,299 | $4,141 |
| Enbrel | 94 | $309,853 | $3,296 |
| Remicade | 45 | $258,888 | $5,753 |
| Simponi | 41 | $164,893 | $4,022 |
| Humira | 38 | $127,360 | $3,352 |
| Xeljanz | 26 | $87,018 | $3,347 |
| Hydroxychloroquine Sulfate | 256 | $61,549 | $240 |
| Methotrexate | 309 | $25,536 | $83 |
| Actemra | 18 | $19,847 | $1,103 |
| Uloric | 24 | $6,186 | $258 |
| Prednisone | 313 | $5,718 | $18 |
| Colchicine | 12 | $3,062 | $255 |
| Celecoxib | 13 | $2,928 | $225 |
| Allopurinol | 72 | $1,954 | $27 |
| Hydrocodone-Acetaminophen | 49 | $1,452 | $30 |
| Proair Hfa | 22 | $1,159 | $53 |
| Alendronate | 83 | $825 | $10 |
| Methylprednisolone | 25 | $671 | $27 |
| Atorvastatin | 18 | $410 | $23 |
| Etodolac | 13 | $396 | $30 |
| Levothyroxine | 16 | $392 | $24 |
| Ibuprofen | 17 | $380 | $22 |
| Triamterene-Hydrochlorothiazid | 20 | $200 | $10 |
| Gabapentin | 19 | $191 | $10 |
| Meloxicam | 20 | $83 | $4 |
2014: 24 drugs
| Humira | 123 | $429,196 | $3,489 |
| Remicade | 45 | $229,572 | $5,102 |
| Enbrel | 66 | $215,147 | $3,260 |
| Simponi | 48 | $136,791 | $2,850 |
| Actemra | 24 | $30,347 | $1,264 |
| Methotrexate | 300 | $24,529 | $82 |
| Colcrys | 43 | $14,177 | $330 |
| Hydroxychloroquine Sulfate | 206 | $9,448 | $46 |
| Celebrex | 18 | $7,236 | $402 |
| Actonel | 17 | $5,675 | $334 |
| Prednisone | 360 | $5,484 | $15 |
| Uloric | 15 | $3,537 | $236 |
| Hydrocodone-Acetaminophen | 44 | $1,501 | $34 |
| Alendronate | 97 | $1,332 | $14 |
| Allopurinol | 96 | $1,172 | $12 |
| Etodolac | 16 | $997 | $62 |
| Methylprednisolone | 23 | $818 | $36 |
| Sulfasalazine Dr | 13 | $742 | $57 |
| Naproxen | 17 | $382 | $22 |
| Omeprazole | 14 | $374 | $27 |
| Meloxicam | 27 | $181 | $7 |
| Ibuprofen | 15 | $170 | $11 |
| Levothyroxine | 13 | $164 | $13 |
| Triamterene-Hydrochlorothiazid | 13 | $124 | $10 |
2013: 26 drugs
| Humira | 107 | $299,689 | $2,801 |
| Remicade | 44 | $175,891 | $3,998 |
| Enbrel | 38 | $152,973 | $4,026 |
| Simponi | 38 | $113,230 | $2,980 |
| Actemra | 24 | $25,688 | $1,070 |
| Methotrexate | 335 | $21,978 | $66 |
| Colcrys | 35 | $10,798 | $309 |
| Celebrex | 13 | $6,076 | $467 |
| Hydroxychloroquine Sulfate | 198 | $4,860 | $25 |
| Uloric | 23 | $4,514 | $196 |
| Actonel | 13 | $3,897 | $300 |
| Prednisone | 391 | $3,777 | $10 |
| Nexium | 11 | $2,395 | $218 |
| Hydrocodone-Acetaminophen | 57 | $1,267 | $22 |
| Alendronate | 89 | $1,232 | $14 |
| Methylprednisolone | 31 | $1,121 | $36 |
| Allopurinol | 101 | $961 | $10 |
| Etodolac | 16 | $622 | $39 |
| Omeprazole | 14 | $399 | $29 |
| Naproxen | 20 | $371 | $19 |
| Meloxicam | 37 | $370 | $10 |
| Glyburide | 11 | $327 | $30 |
| Folic Acid | 30 | $163 | $5 |
| Levothyroxine | 16 | $156 | $10 |
| Ibuprofen | 16 | $152 | $10 |
| Amitriptyline | 13 | $98 | $8 |
Money from drug and device companies
$16,645 in 2025
| 2025 | 11 | 64 | $14,000 | $16,645 |
| 2024 | 15 | 141 | $19,200 | $23,460 |
| 2023 | 14 | 162 | $21,050 | $25,781 |
| 2022 | 10 | 169 | $26,875 | $32,250 |
| 2021 | 14 | 73 | $5,844 | $8,849 |
| 2020 | 12 | 86 | $22,210 | $26,570 |
| 2019 | 12 | 188 | $61,281 | $72,344 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Abbvie | Rinvoq | $15,966 | 30 payments
|
| Amgen | Tavneos | $205 | 6 payments
|
| Novartis Pharmaceuticals | Cosentyx | $202 | 15 payments
|
| Janssen Biotech | Tremfya | $74 | 4 payments
|
| Ucb | Bimzelx | $66 | 3 payments
|
| Aurinia Pharma U.S. | Lupkynis | $28 | 1 payment
|
See all 64 published payments
| Abbvie | Paid to speak or teach · 2025-12-17 | Rinvoq | $2,500 |
| Abbvie | Meals · 2025-12-17 | Rinvoq | $9 |
| Amgen | Meals · 2025-12-17 | Otezla | $5 |
| Janssen Biotech | Meals · 2025-12-15 | Tremfya | $21 |
| Abbvie | Meals · 2025-12-10 | Rinvoq | $14 |
| Amgen | Meals · 2025-12-05 | Evenity | $20 |
| Abbvie | Meals · 2025-12-02 | Rinvoq | $118 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-11-15 | Saphnelo | $27 |
| Ucb | Meals · 2025-11-07 | Bimzelx | $16 |
| Janssen Biotech | Meals · 2025-10-31 | Tremfya | $14 |
| Amgen | Meals · 2025-10-22 | Otezla | $8 |
| Abbvie | Meals · 2025-10-17 | Skyrizi | $11 |
| Novartis Pharmaceuticals | Meals · 2025-10-15 | Cosentyx | $15 |
| Novartis Pharmaceuticals | Meals · 2025-10-14 | Cosentyx | $31 |
| Abbvie | Paid to speak or teach · 2025-10-08 | Skyrizi | $3,500 |
| GlaxoSmithKline | Meals · 2025-09-26 | Benlysta | $22 |
| Novartis Pharmaceuticals | Meals · 2025-09-24 | Cosentyx | $6 |
| Abbvie | Meals · 2025-09-24 | Skyrizi | $83 |
| Abbvie | Meals · 2025-09-19 | Skyrizi | $9 |
| Janssen Biotech | Meals · 2025-09-05 | Tremfya | $14 |
| Novartis Pharmaceuticals | Meals · 2025-09-05 | Cosentyx | $4 |
| Amgen | Meals · 2025-09-05 | Evenity | $33 |
| Ucb | Meals · 2025-08-26 | Bimzelx | $22 |
| Abbvie | Paid to speak or teach · 2025-08-12 | Rinvoq | $2,500 |
| Novartis Pharmaceuticals | Meals · 2025-08-06 | Cosentyx | $16 |
| Kyowa Kirin | Meals · 2025-08-05 | Crysvita | $20 |
| Novartis Pharmaceuticals | Meals · 2025-08-01 | Cosentyx | $12 |
| Abbvie | Meals · 2025-07-29 | Rinvoq | $125 |
| Ucb | Meals · 2025-07-25 | Bimzelx | $29 |
| Novartis Pharmaceuticals | Meals · 2025-07-15 | Cosentyx | $14 |
| Fresenius Kabi USA | Meals · 2025-07-15 | Adalimumab-Aacf | $22 |
| Abbvie | Meals · 2025-07-09 | Skyrizi | $27 |
| Novartis Pharmaceuticals | Meals · 2025-06-30 | Cosentyx | $12 |
| Novartis Pharmaceuticals | Meals · 2025-06-30 | Cosentyx | $2 |
| Novartis Pharmaceuticals | Meals · 2025-06-30 | Cosentyx | $1 |
| Novartis Pharmaceuticals | Meals · 2025-06-27 | Cosentyx | $13 |
| Abbvie | Meals · 2025-06-14 | Rinvoq | $27 |
| Novartis Pharmaceuticals | Meals · 2025-06-04 | Cosentyx | $14 |
| Novartis Pharmaceuticals | Meals · 2025-06-03 | Cosentyx | $25 |
| Abbvie | Paid to speak or teach · 2025-06-02 | Rinvoq | $3,000 |
| Abbvie | Meals · 2025-05-30 | Rinvoq | $21 |
| Abbvie | Travel · 2025-05-30 | Rinvoq | $195 |
| Abbvie | Travel · 2025-05-15 | Rinvoq | $409 |
| Abbvie | Travel · 2025-05-15 | Rinvoq | $346 |
| Abbvie | Meals · 2025-05-15 | Rinvoq | $60 |
| Abbvie | Meals · 2025-05-15 | Rinvoq | $25 |
| Abbvie | Meals · 2025-05-15 | Rinvoq | $70 |
| Abbvie | Meals · 2025-05-15 | Rinvoq | $25 |
| Abbvie | Travel · 2025-05-15 | Rinvoq | $40 |
| Abbvie | Meals · 2025-05-15 | Rinvoq | $150 |
| Abbvie | Meals · 2025-05-05 | Rinvoq | $4 |
| Abbvie | Meals · 2025-05-03 | Rinvoq | $28 |
| Pfizer | Meals · 2025-05-02 | Xeljanz | $14 |
| Aurinia Pharma U.S. | Meals · 2025-04-30 | Lupkynis | $28 |
| Abbvie | Paid to speak or teach · 2025-04-09 | None | $2,500 |
| Abbvie | Meals · 2025-03-22 | Skyrizi | $21 |
| Abbvie | Meals · 2025-03-19 | None | $125 |
| Amgen | Meals · 2025-03-18 | Tavneos | $126 |
| Janssen Biotech | Meals · 2025-02-21 | Simponi Aria | $26 |
| Amgen | Meals · 2025-01-24 | Evenity | $13 |
| Novartis Pharmaceuticals | Meals · 2025-01-22 | Cosentyx | $19 |
| Abbvie | Meals · 2025-01-17 | Rinvoq | $18 |
| Abbvie | Meals · 2025-01-16 | Skyrizi | $6 |
| Novartis Pharmaceuticals | Meals · 2025-01-09 | Cosentyx | $19 |
See earlier years (2024, 2023, 2022, 2021, 2020, 2019)
2024: $23,460
| Abbvie | Rinvoq | $18,183 | 31 payments
|
| Amgen | Otezla | $3,092 | 18 payments
|
| Janssen Biotech | Tremfya | $582 | 28 payments
|
| Novartis Pharmaceuticals | Cosentyx | $545 | 28 payments
|
| Ucb | Cimzia | $335 | 11 payments
|
| AstraZeneca Pharmaceuticals LP | Saphnelo | $187 | 6 payments
|
| Pfizer | Xeljanz | $124 | 4 payments
|
| Fresenius Kabi USA | Idacio | $99 | 3 payments
|
| E.R. Squibb & Sons L.L.C. | Orencia | $89 | 4 payments
|
| Biocon Biologics | Hulio | $53 | 2 payments
|
| Radius Health | Tymlos | $53 | 2 payments
|
| Genzyme | Kevzara | $33 | 1 payment
|
| Boehringer Ingelheim Pharmaceuticals | Cyltezo | $31 | 1 payment
|
| Organon | Renflexis | $29 | 1 payment
|
| Genentech USA | Actemra | $25 | 1 payment
|
2023: $25,781
| AbbVie | Rinvoq | $16,847 | 26 payments
|
| Amgen | Otezla | $6,647 | 27 payments
|
| Janssen Biotech | Tremfya | $997 | 58 payments
|
| Ucb | Cimzia | $330 | 14 payments
|
| Novartis Pharmaceuticals | Cosentyx | $240 | 11 payments
|
| AstraZeneca Pharmaceuticals LP | Saphnelo | $216 | 7 payments
|
| Pfizer | Xeljanz | $114 | 4 payments
|
| Genentech USA | Actemra | $101 | 4 payments
|
| Radius Health | Tymlos | $97 | 3 payments
|
| Fresenius Kabi USA | Idacio | $87 | 3 payments
|
| Boehringer Ingelheim Pharmaceuticals | Cyltezo | $40 | 2 payments
|
| Mylan Institutional | Hulio | $25 | 1 payment
|
| Kyowa Kirin | Crysvita | $21 | 1 payment
|
| Aurinia Pharma U.S. | Lupkynis | $20 | 1 payment
|
2022: $32,250
| Abbvie | Skyrizi | $19,294 | 59 payments
|
| Amgen | Enbrel | $11,326 | 25 payments
|
| Janssen Biotech | Tremfya | $869 | 50 payments
|
| Novartis Pharmaceuticals | Cosentyx | $296 | 16 payments
|
| Ucb | Cimzia | $190 | 8 payments
|
| AstraZeneca Pharmaceuticals LP | Saphnelo | $82 | 3 payments
|
| Pfizer | Xeljanz | $74 | 3 payments
|
| Aurinia Pharma U.S. | Lupkynis | $54 | 2 payments
|
| Alexion Pharmaceuticals | Strensiq | $50 | 2 payments
|
| Genentech USA | Rituxan | $16 | 1 payment
|
2021: $8,849
| Amgen | Enbrel | $5,209 | 13 payments
|
| AbbVie | Rinvoq | $1,952 | 17 payments
|
| Genzyme | Kevzara | $844 | 1 payment
|
| Janssen Biotech | Tremfya | $201 | 19 payments
|
| Ucb | Cimzia | $166 | 5 payments
|
| Alexion Pharmaceuticals | Strensiq | $154 | 2 payments
|
| Novartis Pharmaceuticals | Cosentyx | $150 | 8 payments
|
| Mallinckrodt Hospital Products | Acthar | $34 | 1 payment
|
| GlaxoSmithKline | Benlysta | $31 | 2 payments
|
| Actelion Pharmaceuticals US | Opsumit | $26 | 1 payment
|
| Horizon Therapeutics plc | Krystexxa | $24 | 1 payment
|
| Pfizer | Xeljanz | $22 | 1 payment
|
| E.R. Squibb & Sons L.L.C. | Orencia | $19 | 1 payment
|
| Ultragenyx Pharmaceutical | Crysvita | $17 | 1 payment
|
2020: $26,570
| AbbVie | Rinvoq | $15,524 | 29 payments
|
| Pfizer | Xeljanz | $4,150 | 2 payments
|
| Genzyme | Kevzara | $2,979 | 5 payments
|
| Janssen Biotech | Tremfya | $2,513 | 18 payments
|
| Amgen | Enbrel | $1,107 | 18 payments
|
| Novartis Pharmaceuticals | Cosentyx | $120 | 6 payments
|
| GlaxoSmithKline | Benlysta | $57 | 3 payments
|
| Sobi | Kineret | $26 | 1 payment
|
| Boehringer Ingelheim Pharmaceuticals | Ofev | $25 | 1 payment
|
| E.R. Squibb & Sons L.L.C. | Orencia | $24 | 1 payment
|
| Ucb | Cimzia | $24 | 1 payment
|
| Genentech USA | Rituxan | $20 | 1 payment
|
2019: $72,344
| AbbVie | Rinvoq | $40,770 | 77 payments
|
| Pfizer | Xeljanz | $12,025 | 24 payments
|
| Amgen | Enbrel | $8,543 | 29 payments
|
| Genzyme | Kevzara | $6,800 | 9 payments
|
| Regeneron Healthcare Solutions | Kevzara | $3,509 | 13 payments
|
| Novartis Pharmaceuticals | Cosentyx | $283 | 10 payments
|
| Janssen Biotech | Simponi Aria | $197 | 16 payments
|
| GlaxoSmithKline | Benlysta | $85 | 4 payments
|
| Ucb | Cimzia | $52 | 2 payments
|
| Mallinckrodt Enterprises | Acthar | $42 | 2 payments
|
| Lilly USA | None | $24 | 1 payment
|
| Medexus Pharma | Rasuvo | $16 | 1 payment
|
Checkups this office reported
Medicare did not publish checkup rates for this clinician.
- Medicare’s overall office score
- 75.0 / 100
- Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.
Professional record
- NPI
- 1437142882
- Licence
- CA C36561California C36561: Current · expires 2027-12-31
- Trained
- Ohio State University College of Medicine, 1970 · 56 years ago
- Video visits
- Lists video visits
- Gender
- Male
More record details
- Sole proprietor
- No
- Medicaid ID
- CA GR0046000
- Taxonomy
- Federal specialty code 207RR0500X (207RR0500X)
- Mailing address
- 4000 Civic Center Dr Ste 200a, San Rafael, CA, 94903
- NPI first listed
- 2005-08-31
- NPI last updated
- 2025-03-14
- NPI record certified
- 2025-03-14
This is when the NPI record was last certified, not a medical board exam.
Extra NPI addresses: 2100 Webster St, San Francisco, CA, 94115